Sionna Therapeutics, Inc.

Listed Company

SIONCIK 0002036042NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-75.27M

Total Assets

$325.95M

Equity

$306.83M

Shares Out

45.00M

Op. Cash Flow

$-66.30M

Business

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small-molecule therapies that directly stabilize CFTR’s nucleotide-binding domain 1 (NBD1) to normalize CFTR function in cystic fibrosis patients. Its product portfolio includes NBD1 stabilizers (notably SION-719 and SION-451) and complementary modulators such as galicaftor (SION-2222), SION-109 and navocaftor intended for proprietary dual combinations or as add-ons to the standard of care. The company focuses on R&D and clinical development, supported by licensing arrangements and outsourced manufacturing. It conducts clinical trials in Australia and the U.S. and plans specialty commercialization in the U.S., Canada, Europe and other regions through CF care centers and targeted specialty channels.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Research and development	60	57
General and administrative	29	13
Total operating expenses	89	71
Loss from operations	−89	−71
Interest income	13	8
Other income	419,000	698,000
Total other income	14	9
Net loss	−75	−62
Net loss per share, basic (in dollars per share)	−1.88	−15.99
Net loss per share, diluted (in dollars per share)	−1.88	−15.99
Weighted-average common shares outstanding, basic (in shares)	40	4
Weighted-average common shares outstanding, diluted (in shares)	40	4
Unrealized gain on marketable securities	172,000	368,000
Total other comprehensive gain	172,000	368,000
Comprehensive loss	−75	−61

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-05-31
Cash and cash equivalents	58	38	—	—
Marketable securities, current	177	110	—	—
Prepaid expenses and other current assets	6	3	—	—
Total current assets	241	151	—	—
Property and equipment, net	2	2	—	—
Marketable securities, noncurrent	74	21	—	—
Restricted cash	963,000	962,000	—	—
Operating lease right-of-use asset	7	8	—	10
Other assets	0	3	—	—
Total assets	326	186	—	—
Accounts payable	769,000	1	—	—
Accrued expenses	10	8	—	—
Operating lease liability, current	1	1	—	—
Other current liabilities	6,000	0	—	—
Total current liabilities	12	10	—	—
Operating lease liability, noncurrent	7	9	—	—
Total liabilities	19	19	—	—
Commitments and contingencies (Note 8)	—	—	—	—
Convertible preferred stock, value	0	330	—	—
Preferred stock, $0.001 par value, 10,000,000 and no shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares issued or outstanding as of December 31, 2025 and December 31, 2024	0	0	—	—
Common stock, $0.001 par value, 500,000,000 and 55,200,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 44,723,585 and 4,798,721 shares issued, 44,723,585 and 4,722,763 shares outstanding as of December 31, 2025 and December 31, 2024, respectively	45,000	5,000	—	—
Additional paid-in capital	563	17	—	—
Accumulated other comprehensive income	540,000	368,000	—	—
Accumulated deficit	−256	−181	—	—
Total stockholders equity (deficit)	307	−164	−115	—
Total liabilities, convertible preferred stock and stockholders equity (deficit)	326	186	—	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31
Stock-based compensation expense	12	4
Non-cash operating lease expense	2	2
Amortization of discount on marketable securities	−3	−3
Non-cash expense related to IPR&D acquisition	0	9
Depreciation expense	600,000	700,000
Prepaid expenses and other current assets	−2	−3
Accounts payable	−417,000	467,000
Accrued expenses and other current liabilities	2	1
Operating lease liability	−2	−2
Other assets	0	35,000
Net cash used in operating activities	−66	−53
Purchases of property and equipment	−377,000	−27,000
Purchases of marketable securities	−325	−183
Maturities of marketable securities	207	56
Net cash used in investing activities	−119	−127
Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period	202	0
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs	0	181
Payment of deferred offering costs	0	−3
Exercise of common stock options	4	141,000
Net cash provided by financing activities	206	179
Net increase (decrease) in cash, cash equivalents and restricted cash	21	−733,000
Conversion of convertible preferred stock into common stock upon closing of initial public offering	330	0
Offering costs transferred to additional paid in capital	4	0
Deferred offering costs in accrued expenses	0	492,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro